Morning Momentum: Today's Big Profit Plays!

You are receiving this newsletter as a subscriber to Premium Stock Alerts

Hello Part-time Trader…👋

Stocks are surging on in pre market trading Monday as data from last week fueled optimism about a potential interest rate cut by the Federal Reserve. Friday's data showed a decline in inflation based on the core PCE index, a key measure for the Fed.

This slowdown in inflation raises the possibility of a rate cut before year-end, which could be a boon for stocks.

As the second half of the year kicks off, traders will navigate a shortened week due to the Fourth of July holiday on Thursday. This week kicks off with a bang! Investors will be closely watching the release of the ISM manufacturing index on Monday, a key indicator of factory activity.

Happening Today

✓ 09:45 AM ET – S&P Global US Manufacturing PMI (Jun)

10:00 AM ET – Construction Spending (MoM) (May)

✓ 10:00 AM ET – ISM Manufacturing Employment (Jun)

✓ 10:00 AM ETISM Manufacturing PMI (Jun)

✓ 10:00 AM ET – ISM Manufacturing Prices (Jun)

✓ 12:00 PM ET – Atlanta Fed GDPNow (Q3)

Superbug Crisis: Is This Unknown Company Our Last Hope?

Antibiotic-resistant superbugs could claim 10 million lives annually by 2050. A small company's partnership with a renowned university might hold the key to our survival.

Learn about the potentially life-saving technology that could solve the superbug crisis and attract billion-dollar acquisitions


Market futures are up, with the S&P 500, Dow, and NASDAQ all showing gains of 0.22% to 0.23%.



 ⬆️ 0.23%



 ⬆️ 0.22%



  ⬆️ 0.23%


Market declines led by Consumer Discretionary and Communication Services, with modest gains in Energy and Financials.




Consumer Discretionary


-1.36% 🔴

Consumer Staples


-0.46% 🔴



+0.42% 🟢



+0.38% 🟢

Health Care


-0.08% 🔴



+0.08% 🟢



-0.02% 🔴

Real Estate


+0.62% 🟢

Information Technology


-0.43% 🔴

Communication Services


-1.63% 🔴



-1.08% 🔴


Buy a stock when it crosses this line on the chart

I've used this line for the past 30 years and I'm one of the most well-known traders on Wall Street. Most don't use it nor know it exists. This line gets you in and out of big name stocks like Nvidia, Tesla and Netflix… then gets you out before trouble. This free indicator would've told you to get out of stocks in February 2020.

Here's the line to follow.

PreMarket Unusual Volume Stocks

📈 Nukkleus Inc (NUKK): Nukkleus Inc saw a significant increase in trading activity with a volume of 9,390,369, well above its average volume of 301.67. This notable rise in volume corresponds with an 18.56% price change, reflecting heightened market interest.

📈 Loop Media Inc (LPTV): Loop Media Inc experienced a substantial rise in volume, trading 28,455,341 shares compared to its average of 1,021.81. This dramatic increase in trading volume resulted in an 81.19% price change, indicating strong investor activity.

📈 Lion Group Holding Ltd ADR (LGHL): Lion Group Holding Ltd ADR saw its trading volume surge to 7,069,678, significantly higher than its average of 489.58. The stock's price change of 15.78% mirrors this spike in trading volume.

📈 Golden Heaven Group Holdings Ltd (GDHG): Golden Heaven Group Holdings Ltd saw its volume rise to 24,303,656, far exceeding its average of 5,446.38. The stock's 50.33% price change reflects the surge in trading volume.

📈 Complete Solaria Inc. (CSLR): Complete Solaria Inc. saw its volume rise to 3,522,635 from an average of 1,484.44. This increase in trading activity resulted in a 38.39% price change, underscoring the market's response to the heightened volume.


AI's NEXT Magnificent Seven

The Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.

But the Man Who Called Nvidia at $1.10 Says "AI's Next Magnificent Seven Could Do It Even Faster."

See His Breakdown of the Seven Stocks You Should Own Here.

Premarket Picks

Complete Solaria, Inc. (CSLR) surged 20.53% in pre-market trading, reaching $1.35 per share after announcing the cancellation of $67.6 million in debt from its balance sheet. The company has been released from its obligations under that debt by its two private equity providers, Carlyle and Kline Hill Partners.

Babcock & Wilcox Enterprises, Inc. (BW) experienced a pre-market increase of 13.79%, reaching $1.65 per share. This followed news of an agreement to sell its Denmark-based renewable parts and services subsidiary.

Arbe Robotics Ltd. (ARBE) saw a 7.85% gain in pre-market trading, reaching $2.06 per share. The increase came after announcing that one of the top ten OEMs worldwide has selected Arbe's chipset for developing its next-generation imaging radar for serial production.

Below is a list of other hot stocks in pre-market today:

Pre Market Gainers

Pre Market Change

Pre Market Volume
































Nvidia's march to $5 trillion

No company has ever been worth $5 trillion...

But Nvidia is in prime position to be the first.

You see, Nvidia just pivoted to a massive new Superproject.

This move's key to the future of AI.

And it could set Nvidia up to dominate the sector for a long while.

Click here to see how Nvidia's march to $5 trillion could impact its partners.

Important FDA 

Recently Announced

On June 26, 2024, Verona Pharma plc (VRNA) announced that the FDA approved its drug Ensifentrine, which will be marketed under the brand name Ohtuvayre. This approval is for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients, marking a significant milestone for the company.

Merck & Co Inc. (MRK) received a Complete Response Letter (CRL) from the FDA on June 26, 2024, for Patritumab deruxtecan (HER3-DXd). The CRL was issued due to inspection findings at a third-party manufacturer, impacting the drug's application for use in patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

On June 26, 2024, AbbVie (ABBV) announced that the FDA approved its drug Epcoritamab-bysp for the expanded treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. This approval allows AbbVie to provide a new therapeutic option for this patient population.

Similarly, on June 26, 2024, GENMAB A/S (GMAB) received FDA accelerated approval for Epcoritamab-bysp. This approval is for treating relapsed or refractory follicular lymphoma (FL) in adult patients after two or more lines of systemic therapy, enhancing GENMAB’s oncology portfolio.

Rocket Pharmaceuticals, Inc. (RCKT) faced a setback on June 28, 2024, when the FDA issued a Complete Response Letter for KRESLADI (RP-L201). This drug was intended for the treatment of severe Leukocyte Adhesion Deficiency-I, but the CRL has delayed its approval, requiring the company to address the FDA’s concerns.


The Perfect Storm for Crypto Profits

JPMorgan, Blackrock, and Singapore are betting big on blockchain. And one coin stands to benefit most as trillions in assets move on-chain. This is your moment to get in before the masses catch on. Your window is closing.

See the #1 coin to buy now

Upcoming Announcements

On July 7, 2024, Arcutis Biotherapeutics Inc. (ARQT) is expecting a critical FDA decision on their supplemental New Drug Application (sNDA) for Roflumilast Cream 0.15%. This cream is designed to treat atopic dermatitis in adults and children as young as six years old. Approval of this treatment could provide a new option for managing this common and often challenging skin condition.

Phathom Pharmaceuticals Inc. (PHAT) is anticipating an important FDA decision on July 19, 2024, regarding their New Drug Application (NDA) for VOQUEZNA (vonoprazan) Tablets. These tablets aim to treat heartburn associated with non-erosive gastroesophageal reflux disease (GERD). If approved, VOQUEZNA could offer a new therapeutic alternative for patients suffering from this prevalent digestive disorder.

Happy investing,

Maeve Grace
Editor In Chief
Premium Trade Alerts

Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.

Join the conversation

or to participate.